Linked Life Data

17719337

Source:http://linkedlifedata.com/resource/pubmed/id/17719337

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2007-8-27
pubmed:abstractText
The purpose of this study was to identify risk factors of Torsade de pointes (TdP) ventricular tachycardia in patients medicated with a class III antiarrhythmic drug (dofetilide) and left ventricular systolic dysfunction with heart failure (HF) or recent myocardial infarction (MI). The 2 Danish Investigations of Arrhythmia and Mortality on Dofetilide (DIAMOND) studies enrolled patients with HF (DIAMOND-HF) or MI (DIAMOND-MI) and left ventricular systolic dysfunction. The present analysis includes only patients treated solely with dofetilide. The incidence of TdP was 2.1% (32 of 1,511). Twenty-five of the incidences occurred in the DIAMOND-HF study and 7 cases in the DIAMOND-MI study (p = 0.0015). TdP was more frequent in women than in men (47% vs 28%, p = 0.02). Risk factors for developing TdP were female gender (odds ratio 2.2, 95% confidence interval [CI] 1.0 to 5.0), MI within 8 weeks (odds ratio 0.3, 95% CI 0.1 to 0.7), being in New York Heart Association class III or IV (odds ratio 3.2, 95% CI 1.2 to 8.6), and baseline QTc duration (odds ratio 1.14, 95% CI 1.00 to 1.30) per 10 ms. Women with chronic HF, QTc duration >400 ms. and New York Heart Association class III or IV had a risk of TdP of 10%, whereas no TdP episodes were observed in patients with QTc duration <400 ms. In conclusion, severity of HF, female gender, and QTc duration make it possible to identify patients with a high risk of early TdP when treated with dofetilide. Patients with recent MI less often had TdP compared with patients with chronic HF.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0002-9149
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
100
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
876-80
pubmed:meshHeading
pubmed-meshheading:17719337-Aged, pubmed-meshheading:17719337-Aged, 80 and over, pubmed-meshheading:17719337-Anti-Arrhythmia Agents, pubmed-meshheading:17719337-Atrial Fibrillation, pubmed-meshheading:17719337-Cardiac Output, Low, pubmed-meshheading:17719337-Cause of Death, pubmed-meshheading:17719337-Double-Blind Method, pubmed-meshheading:17719337-Electrocardiography, pubmed-meshheading:17719337-Female, pubmed-meshheading:17719337-Forecasting, pubmed-meshheading:17719337-Heart Arrest, pubmed-meshheading:17719337-Humans, pubmed-meshheading:17719337-Male, pubmed-meshheading:17719337-Middle Aged, pubmed-meshheading:17719337-Myocardial Infarction, pubmed-meshheading:17719337-Phenethylamines, pubmed-meshheading:17719337-Placebos, pubmed-meshheading:17719337-Potassium Channel Blockers, pubmed-meshheading:17719337-Risk Factors, pubmed-meshheading:17719337-Sex Factors, pubmed-meshheading:17719337-Sulfonamides, pubmed-meshheading:17719337-Time Factors, pubmed-meshheading:17719337-Torsades de Pointes, pubmed-meshheading:17719337-Ventricular Dysfunction, Left
pubmed:year
2007
pubmed:articleTitle
Risk factors and predictors of Torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving Dofetilide.
pubmed:affiliation
Department of Cardiology and Endocrinology, University Hospital of Copenhagen, Frederiksberg Hospital, Frederiksberg, Denmark. henrysloth@dbmail.dk
pubmed:publicationType
Journal Article, Comparative Study, Randomized Controlled Trial